ArticleBMC public health2025
Epidemiological characteristics of human papillomavirus in Guangzhou, China-A retrospective analysis of 76,898 cases.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPersistent infection with human papillomavirus (HPV) plays a key role in cervical cancer development. This study aimed to investigate the epidemiological trends and genotype distribution of HPV from 2013 to 2021 in Guangzhou, China.
methodsA retrospective analysis was conducted on 76,898 women who attended either the Gynecology Outpatient Department or underwent routine health examinations at the Health Management Center of Sun Yat-sen University. HPV testing was performed using hybrid capture-based assays, capable of detecting 15 high-risk and 6 low-risk HPV genotypes. Chi-square tests were used to compare HPV genotype prevalence between the two groups and to assess differences in single vs. multiple infections. The Cochran-Armitage trend test was applied to evaluate temporal trends in HPV prevalence.
resultsThe overall HPV prevalence was 15.21% [95% CI: 14.95-15.45%], with 16.52% [95% CI: 16.23-16.82%] among 60,399 gynecological outpatients and 10.35% [95% CI: 9.90-10.83%] among 16,499 healthy women. The most prevalent genotypes were HPV-52 (3.31%, 95% CI: 3.18 - 3.43%), HPV-16 (2.30%, 95% CI: 2.2 - 2.41%), and HPV-58 (1.97%, 95% CI: 1.88 - 2.07%), followed by HPV-CP8304 (1.48%, 95% CI: 1.39 - 1.56%), HPV-39 (1.39%, 95% CI: 1.31 - 1.47%). HPV-16, 18, 31, 33, 53, 66, and CP8304 declined (p < 0.05), while HPV-35, 39, 42, 43, 44, 51, 56, and 68 increased (p < 0.05). Single- and multiple-type HPV infections had prevalences of 11.70% [ 95% CI: 11.47-11.93%]and 3.50% [95% CI: 3.37-3.63%], respectively. Both were significantly more prevalent in gynecological outpatients than in health examination participants (p < 0.001). The age distribution of HPV-positive individuals peaked at 30 years.
conclusionsThis study highlights the high prevalence of HPV-52, HPV-16, and HPV-58 in Guangzhou, with single-type infections being predominant. While some genotypes declined, others showed an increasing trend, emphasizing the need for continuous surveillance. These findings offer epidemiological insights to guide targeted vaccination policies. Given the lack of vaccination data, future studies integrating vaccination history and clinical outcomes are needed to clarify HPV genotype trends and their role in cervical cancer prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.